Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II
Conditions
Interventions
Placebo
KVD900 600 mg
+1 more
Locations
66
United States
KalVista Investigative Site
Birmingham, Alabama, United States
KalVista Investigative Site
Scottsdale, Arizona, United States
KalVista Investigative Site
Little Rock, Arkansas, United States
KalVista Investigative Site
San Diego, California, United States
KalVista Investigative Site
San Diego, California, United States
KalVista Investigative Site
Santa Monica, California, United States
Start Date
February 22, 2022
Primary Completion Date
December 31, 2023
Completion Date
December 31, 2023
Last Updated
May 2, 2025
NCT07298447
NCT06960213
NCT06842823
NCT06573723
NCT06634420
NCT05392114
Lead Sponsor
KalVista Pharmaceuticals, Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions